-
ICD-10-CM Codes
›
-
E00-E89
›
-
E70-E88
›
-
E75-
›
-
2023 ICD-10-CM Diagnosis Code E75.02
2023 ICD-10-CM Diagnosis Code E75.02
Tay-Sachs disease
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
- E75.02 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM E75.02 became effective on October 1, 2022.
- This is the American ICD-10-CM version of E75.02 - other international versions of ICD-10 E75.02 may differ.
The following code(s) above
E75.02 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
E75.02:
- E00-E89
2023 ICD-10-CM Range E00-E89
Endocrine, nutritional and metabolic diseasesNote- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Type 1 Excludes- transitory endocrine and metabolic disorders specific to newborn (P70-P74)
Endocrine, nutritional and metabolic diseases - E70-E88
2023 ICD-10-CM Range E70-E88
Metabolic disordersType 1 Excludes- androgen insensitivity syndrome (E34.5-)
- congenital adrenal hyperplasia (E25.0)
- hemolytic anemias attributable to enzyme disorders (D55.-)
- Marfan's syndrome (Q87.4)
- 5-alpha-reductase deficiency (E29.1)
Type 2 Excludes- Ehlers-Danlos syndromes (Q79.6-)
Metabolic disorders - E75
ICD-10-CM Diagnosis Code E75
Disorders of sphingolipid metabolism and other lipid storage disorders
2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
Disorders of sphingolipid metabolism and other lipid storage disorders
Approximate Synonyms
Clinical Information
- A rare, fatal, autosomal recessive lipid storage disorder caused by mutations in the hexa gene. It is characterized by deficiency of beta-hexosaminidase a, resulting in accumulation of gangliosides in the neurons of the brain and spinal cord. Signs and symptoms include progressive deterioration of the mental and physical abilities early in life, accompanied by blindness, deafness, muscle atrophy, and paralysis.
- An autosomal recessive neurodegenerative disorder characterized by the onset in infancy of an exaggerated startle response, followed by paralysis, dementia, and blindness. It is caused by mutation in the alpha subunit of the hexosaminidase a resulting in lipid-laden ganglion cells. It is also known as the b variant (with increased hexosaminidase b but absence of hexosaminidase a) and is strongly associated with ashkenazic jewish ancestry.
- Autosomal recessive inherited gangliosidosis characterized by the onset in the first 6 months of life of an exaggerated startle response, delay in psychomotor development, hypotonia (followed by spasticity), visual loss, and a macular cherry red spot; hexosaminidase a is deficient, leading to the accumulation of gm2 ganglioside in neurons of the central nervous system and retina; this condition is strongly associated with ashkenazic jewish ancestry.
- Tay-sachs disease is a rare, inherited disorder. It causes too much of a fatty substance to build up in tissues and nerve cells of the brain. This buildup destroys the nerve cells, causing mental and physical problems. Infants with tay-sachs disease appear to develop normally for the first few months of life. Then, as nerve cells become distended with fatty material, mental and physical abilities deteriorate. The child becomes blind, deaf, and unable to swallow. Muscles begin to atrophy and paralysis sets in. Even with the best of care, children with tay-sachs disease usually die by age 4.tay-sachs is most common in eastern european ashkenazi jews. A blood test can determine if you carry or have the disease. There is no cure. Medicines and good nutrition can help some symptoms. Some children need feeding tubes.
ICD-10-CM E75.02 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
- 056 Degenerative nervous system disorders with mcc
- 057 Degenerative nervous system disorders without mcc
Convert E75.02 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
- Gangliosidosis E75.10
ICD-10-CM Diagnosis Code E75.10
Unspecified gangliosidosis
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
- GM2 E75.00
ICD-10-CM Diagnosis Code E75.00
GM2 gangliosidosis, unspecified
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
- Sachs' amaurotic familial idiocy or disease E75.02
- Sachs-Tay disease E75.02
- Tay-Sachs amaurotic familial idiocy or disease E75.02
ICD-10-CM Codes Adjacent To E75.02
E74.81 Disorders of glucose transport, not elsewhere classified
E74.810 Glucose transporter protein type 1 deficiency
E74.818 Other disorders of glucose transport
E74.819 Disorders of glucose transport, unspecified
E74.89 Other specified disorders of carbohydrate metabolism
E74.9 Disorder of carbohydrate metabolism, unspecified
E75 Disorders of sphingolipid metabolism and other lipid storage disorders
E75.02
Tay-Sachs disease
E75.09 Other GM2 gangliosidosis
E75.1 Other and unspecified gangliosidosis
E75.10 Unspecified gangliosidosis
E75.2 Other sphingolipidosis
E75.21 Fabry (-Anderson) disease
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.